|
|
ABO blood group does not influence Child‐Pugh A cirrhosis outcome: An observational study from CIRRAL and ANRS CO12 CIRVIR cohorts
Isabelle Ollivier-Hourmand
,
Yohann Repesse
,
Pierre Nahon
,
Cendrine Chaffaut
,
Thông Dao
,
et al.
Article dans une revue
hal-03553907v1
|
Partager
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Sofosbuvir plus Velpatasvir plus Voxilaprevir in Daa Failure Patients with Cirrhosis. Final Results of the French Compassionate Use Program
Christophe Hezode
,
Dominique Guyader
,
Eric Nguyen-Khac
,
Dominique Larrey
,
Regine Truchi
,
et al.
Hepatology, 2018, 68 (1), pp.374A
Article dans une revue
hal-03590862v1
|
Partager
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Extrahepatic cancers are the leading cause of death in patients achieving hepatitis B virus control or hepatitis C virus eradication
Manon Allaire
,
Pierre Nahon
,
Richard Layese
,
Valérie Bourcier
,
Carole Cagnot
,
et al.
Article dans une revue
hal-02648452v1
|
Partager
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Integrating genetic variants into clinical models for hepatocellular carcinoma risk stratification in cirrhosis
Pierre Nahon
,
Jessica Bamba-Funck
,
Richard Layese
,
Eric Trépo
,
Jessica Zucman-Rossi
,
et al.
Article dans une revue
hal-03883705v1
|
Partager
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Changes in serum bile acid levels associated with bezafibrate add-on therapy in patients with primary biliary cholangitis and inadequate biochemical response to ursodeoxycholic acid: results from the BEZURSO trial (NCT01654731)
Christophe Corpechot
,
Olivier Chazouilleres
,
Lydie Humbert
,
Alexandra Rousseau
,
Antonia Le Gruyer
,
et al.
Hepatology, 2017, 66 (1, SI), pp.168A
Article dans une revue
hal-03590928v1
|
Partager
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Sofosbuvir plus velpatasvir plus voxilaprevir in DAA failure patients with cirrhosis: Final results of the French compassionate use program
Christophe Hezode
,
Dominique Guyader
,
Eric Nguyen-Khac
,
Dominique Larrey
,
Regine Truchi
,
et al.
Article dans une revue
hal-03590860v1
|
Partager
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Large-scale screening of lipase acid deficiency in at risk population
Abdellah Tebani
,
Bénédicte Sudrié-Arnaud
,
Hela Boudabous
,
Anais Brassier
,
Rodolphe Anty
,
et al.
Article dans une revue
hal-03223991v1
|
Partager
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Efficacy and safety of elbasvir/grazoprevir for 8 or 12 weeks for hepatitis C virus genotype 4 infection: A randomized study
Tarik Asselah
,
Stanislas Pol
,
Christophe Hezode
,
Veronique Loustaud-Ratti
,
Vincent Leroy
,
et al.
Article dans une revue
hal-03590858v1
|
Partager
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Unresectable hepatocellular carcinoma at dawn of immunotherapy era: real-world data from the French prospective CHIEF cohort
Eric Nguyen-Khac
,
Pierre Nahon
,
Olivier Ganry
,
Hajer Ben Khadhra
,
Philippe Merle
,
et al.
Article dans une revue
hal-04182844v1
|
Partager
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Daclatasvir plus sofosbuvir with or without ribavirin in genotype 3 patients from a large French multicenter compassionate use program
Christophe Hézode
,
Victor De Ledinghen
,
Hélène Fontaine
,
Fabien Zoulim
,
Pascal Lebray
,
et al.
Article dans une revue
hal-01380169v1
|
Partager
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Efficacy and Safety of Elbasvir/Grazoprevir for 8 or 12 Weeks in Participants with Hepatitis C Virus Genotype 4 Infection
Tarik Asselah
,
Stanislas Pol
,
Christophe Hezode
,
Veronique Loustaud Ratti
,
Vincent Leroy
,
et al.
Hepatology, 2018, 68 (1), pp.385A
Article dans une revue
hal-03590861v1
|
Partager
Gmail
Facebook
Twitter
LinkedIn
More
|